Posadas Research Lab Cedars-Sinai Skip to content Close Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog English English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Translation is unavailable for Internet Explorer Cedars-Sinai Home 1-800-CEDARS-1 1-800-CEDARS-1 Close Find a Doctor Locations Programs & Services Health Library Patient & Visitors Community My CS-Link RESEARCH clear Go Close Navigation Links Academics Faculty Development Community Engagement Calendar Research Research Areas Research Labs Departments & Institutes Find Clinical Trials Research Cores Research Administration Basic Science Research Clinical & Translational Research Center (CTRC) Technology & Innovations News & Breakthroughs Education Graduate Medical Education Continuing Medical Education Graduate School of Biomedical Sciences Professional Training Programs Medical Students Campus Life Office of the Dean Simulation Center Medical Library Program in the History of Medicine About Us All Education Programs Departments & Institutes Faculty Directory Posadas Lab This translational research laboratory is studying the biology of cancer metastasis, with emphasis on the model of prostate cancer. The ultimate goal of all our laboratory research projects is to develop new therapies to prevent metastatic progression of and to cure advanced prostate cancers. The Posasdas Laboratory is affiliated with the Urologic Oncology Research Program at the Samuel Oschin Comprehensive Cancer Institute and the Department of Medicine, Hematology Oncology Division. Personal Statement Edwin Posadas, MD, is medical director of the Urologic Oncology Program of the Samuel Oschin Comprehensive Cancer Institute and the clinical co-chief of the Division of Hematology/Oncology of the Department of Medicine at Cedars-Sinai. He holds academic rank of associate professor in the Department of Medicine at Cedars-Sinai and the David Geffen School of Medicine at the University of California, Los Angeles. Edwin Posadas, MD Breakthrough Research Areas FYN in prostate cancer Biology of circulating tumor cells (CTCs) Internal Collaborations Bhowmick Laboratory Chung Laboratory Di Vizio Laboratory Freeman Laboratory H. L. Kim Laboratory J. Kim Laboratory Samuel Oschin Comprehensive Cancer Institute Urologic Oncology Program Meet Our Team Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Posadas Laboratory, whose dedicated efforts lead to groundbreaking discoveries. View Our Team Publications Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G. Urol Oncol. 2015 Sep 8. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Liang AJ, Hodara E, Zhau HE, Hou S, Ahmed RS, Luthringer DJ, Huang J, Li KC, Chung LW, Ke Z, Tseng HR, Posadas EM. Cancer. 2015;121(18):3240-3251. miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW. Clin Cancer Res. 2014;20(24):6559-6569. Contact the Posadas Lab 8700 Beverly Blvd. Davis Building, Room 5094C Los Angeles, CA 90048 310-423-1510 Send a Message Please ensure Javascript is enabled for purposes of website accessibility